XTNT Xtant Medical Holdings, Inc.
Surgical & Medical Instruments & Apparatus · NYSE · SEC CIK 1453593 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-24.4%
TTM net income YoY-1,014.2%
TTM EPS YoY-1,200.0%
Revenue 3-yr CAGR8.6%
Net income 3-yr CAGR—
Margins
Gross margin56.4%
Operating margin-16.0%
Net margin-15.9%
FCF margin-6.1%
EBITDA margin-12.6%
Returns
ROE-36.5%
ROA-17.6%
ROIC (approx.)-26.2%
Asset turnover1.11x
Leverage & solvency
Liabilities / assets50.5%
Debt / equity0.27x
Current ratio2.00x
Interest coverage-6.56x
Cash quality & payout
Operating cash flow / net income0.31x
Accruals ratio-12.2%
Payout ratio—
Capex / revenue1.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $133.93M | $117.27M | $91.30M | $57.97M | $55.26M |
| Cost of revenue | $49.65M | $49.05M | $35.84M | $25.83M | $22.77M |
| Gross profit | $84.27M | $68.22M | $55.47M | $32.14M | $32.49M |
| R&D expense | $2.10M | $2.38M | $1.34M | $915,000 | $870,000 |
| SG&A expense | $29.38M | $28.69M | $25.85M | $15.46M | $14.45M |
| Operating income | $7.28M | -$12.07M | -$10.16M | -$6.75M | -$3.85M |
| Interest expense | $3.67M | $4.16M | $2.94M | $1.69M | $995,000 |
| Pretax income | $7.00M | -$16.26M | -$1.04M | -$8.42M | -$4.85M |
| Income tax | $2.03M | $187,000 | -$1.70M | $69,000 | — |
| Net income | $4.97M | -$16.45M | $660,000 | -$8.48M | -$4.85M |
| EBITDA | $12.51M | -$7.85M | -$6.98M | -$5.46M | -$2.52M |
| EPS (basic) | 0.04 | -0.12 | 0.01 | -0.09 | -0.06 |
| EPS (diluted) | 0.03 | -0.12 | 0.01 | -0.09 | -0.06 |
| Weighted avg. shares (diluted) | 150.04M | 133.67M | 126.79M | 94.09M | 85.46M |
| Balance sheet | |||||
| Cash & equivalents | $17.05M | $6.20M | $5.71M | $20.30M | $18.24M |
| Receivables | $17.80M | $20.66M | $21.70M | $10.85M | $7.15M |
| Inventory | $30.26M | $38.63M | $36.88M | $17.29M | $17.95M |
| Current assets | $78.25M | $67.12M | $64.87M | $49.32M | $44.33M |
| PP&E, net | $6.20M | $10.13M | $8.69M | $5.79M | $5.21M |
| Goodwill | $6.07M | $7.30M | $7.30M | $3.21M | $3.21M |
| Intangibles | $299,000 | $8.36M | $10.09M | $344,000 | $400,000 |
| Total assets | $94.14M | $93.84M | $92.61M | $60.23M | $54.69M |
| Current liabilities | $29.48M | $28.58M | $22.99M | $15.22M | $11.08M |
| Short-term debt | $3.50M | — | — | $2.33M | — |
| Long-term debt | $11.03M | $22.04M | $17.17M | $9.69M | $11.79M |
| Total debt | $14.53M | $22.04M | $17.17M | $12.02M | $11.79M |
| Total liabilities | $43.19M | $50.87M | $41.26M | $26.06M | $23.81M |
| Shareholders' equity | $50.95M | $42.96M | $51.35M | $34.17M | $30.88M |
| Net debt | -$2.53M | $15.84M | $11.45M | -$8.28M | -$6.46M |
| Shares outstanding | 140.04M | 139.05M | 130.18M | 108.87M | 87.07M |
| Cash flow statement | |||||
| Operating cash flow | $12.55M | -$11.90M | -$9.52M | -$5.34M | $439,000 |
| Capital expenditure | $2.38M | $4.11M | $1.46M | $1.76M | $2.12M |
| Free cash flow | $10.16M | -$16.01M | -$10.97M | -$7.11M | -$1.68M |
| Investing cash flow | $7.90M | -$3.73M | -$24.78M | -$1.56M | -$1.89M |
| Financing cash flow | -$9.57M | $16.07M | $19.69M | $9.02M | $17.50M |
| Depreciation & amortization | $5.22M | $4.22M | $3.17M | $1.29M | $1.33M |
| Stock-based compensation | $2.89M | $4.12M | $2.74M | $2.46M | $2.21M |
Free plan shows the latest 5 periods; Pro shows all 16 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.